Xpat Tech is biotech company. Due COVID-19 increases in volume, profits and stock price have been soaring. However, it was just announced that one of the Xpat's promising pharmaceuticals failed a late-stage drug trial. What type of risk is the possibility of a failed drug trial and, according to CAPM, should investors care about this risk? Systematic risk: No, investors do not care about this risk Systematic risk: Yes, investors care about this risk Firm-specific risk: Yes, investors care about this risk Firm-specific risk: No, investors do not care about this risk